250 words); Main text (3336 words -without panel); Figures (3); Table (1); References (36) Abstract Background. Artemisinin resistance in Plasmodium falciparum has been documented in Cambodia, Thailand, Myanmar, and Vietnam. This clinical phenotype manifests as a long parasite clearance half-life during administration of artemisinin monotherapy or artemisinin-based combination therapy. The lack of in-vitro and ex-vivo correlates of artemisinin resistance makes studying this phenotype costly and logistically challenging.
Introduction
Following the World Health Organization's recommendation 1 to use artemisinin-based combination therapies (ACTs) for Plasmodium falciparum malaria, the burden of this disease fell substantially. 2 As with earlier antimalarial drugs, 3 parasite resistance to artemisinin and its derivatives has emerged in southeast Asia. Since first being reported in 2008 and 2009 from Battambang 4 and Pailin 5 provinces in western Cambodia, artemisinin-resistant P falciparum malaria has been documented elsewhere in western Cambodia, 6, 7 western Thailand, 8 southern Myanmar, 9 and southern Vietnam. 10 Artemisinin resistance threatens malaria control, treatment, and elimination efforts worldwide. 11, 12 To prevent the spread of artemisinin-resistant parasites throughout southeast Asia and to Africa, rapid detection of novel artemisinin resistance foci and implementation of containment interventions are a top priority. 13 Although artemisinin resistance has not been precisely defined, it is presently recognized as a relatively slow parasite clearance rate in patients receiving an artemisinin or ACT. 14 The parasite clearance half-life can be estimated from frequent parasite density counts in patients with initial parasite densities ≥10,000 per µL of blood (ie, ≥0·2% parasitemia). 15 In areas of low malaria transmission like Cambodia, parasite clearance studies require screening thousands of febrile individuals over entire transmission seasons to enroll few (<5%) patients who meet inclusion criteria and agree to several days of hospitalization. Such studies are thus logistically and financially demanding, as well as inconvenient for patients and their families. There is thus an urgent need to develop in-vitro and ex-vivo assay readouts that correlate with parasite clearance half-life. In-vitro readouts (ie, those obtained from culture-adapted parasite lines in the laboratory) may be useful in elucidating the molecular basis of artemisinin resistance by providing robust phenotypes for genome-wide association studies or the experimental validation of candidate molecular markers. Ex-vivo readouts (ie, those obtained from uncultured parasite isolates collected directly from patients in the field) may be useful in mapping the geographical spread or worsening of artemisinin resistance in real-time, thus providing actionable information for national malaria control programs. To date, consistent and significant correlations between half-lives and readouts from any invitro or ex-vivo artemisinin susceptibility assay (eg, elevated IC 50 value -the drug concentration that inhibits parasite growth by 50%) have not been demonstrated. [4] [5] [6] One potential reason for this observation is that parasites in these assays are exposed to very low concentrations of dihydroartemisinin (DHA, the active metabolite of all artemisinins) for 48-72 h, while parasites in vivo are exposed to much higher concentrations of DHA for only 1-2 h. Artemisinin resistance in drugselected P falciparum lines has been associated with decreased susceptibility of ring-stage parasites [16] [17] [18] and, in some lines, mature trophozoite-stage parasites as well. 16, 19 Using a novel in-vitro assay (Ringstage Survival Assay, RSA) 20 ( figure 1A) , we recently measured the susceptibility of 0-12 h post-invasion rings to a pharmacologically-relevant exposure (700 nM for 6 h) to DHA. We observed a 17-fold higher survival rate of culture-adapted parasite isolates from Pailin province, an area of artemisinin resistance in western Cambodia, compared to those from Ratanakiri province, an area of artemisinin sensitivity in eastern Cambodia. How this geographic dichotomy relates to the clinical artemisinin resistance phenotype is unknown, as ring-stage parasites from patients with known parasite clearance kinetics
have not yet been tested in the RSA.
The objectives of the present study were: (i) to assess whether an in-vitro RSA can distinguish cultureadapted P falciparum isolates from patients with slow-or fast-clearing infections; (ii) to investigate the stage-dependent susceptibility of parasites to DHA in the in-vitro RSA, and (iii) to assess whether an exvivo RSA can identify artemisinin-resistant P falciparum infections in patients with malaria. To mimic the in-vivo exposure of circulating, ring-stage parasites to pharmacologically-relevant doses of DHA, we exposed synchronized, ring-stage parasites to brief, high-dose pulses of this drug. In a retrospective study using culture-adapted parasites collected in 2010, 6 we demonstrate increased survival of 0-3 h ring-stage parasites from slow-clearing compared to fast-clearing infections. In a prospective study, we show that ex-vivo parasite survival rates correlate significantly with in-vivo parasite clearance half-lives, and reliably detect artemisinin-resistant parasites in patients. These data identify the artemisininresistant developmental stage of clinical P falciparum isolates, and provide in-vitro and ex-vivo phenotypes for investigating the molecular basis and geographic distribution of artemisinin resistance.
Methods

Study design, patients, and drug therapy
We conducted two clinical studies in Cambodia to measure therapeutic responses to artesunate: in 2009-2010 in Pursat province (western Cambodia), 6 The 2009-2010 study in Pursat was previously reported. 6 Patients were treated with oral doses of 4 mg/kg artesunate at 0, 24, and 48 h, and then 15 mg/kg mefloquine at 72 h and 10 mg/kg mefloquine at 96 h.
In the 2012 study, children over 1 year of age and non-pregnant adults with uncomplicated falciparum malaria (parasite density ≥10,000 and ≤200,000 per µL of blood) were enrolled if written informed consent was obtained from the patient or, if a child, from a parent or guardian. Patients with severe malaria, P vivax infection, hematocrit <25%, antimalarial drug use in the last 7 days, or known allergy to artemisinins or piperaquine were excluded. Patients were treated with oral doses of Duo-Cotecxin® (containing 40 mg DHA and 320 mg piperaquine per tablet; Holleypharma, China) at 0, 24, and 48 h. The doses were based on body weight as follows: 0·5 tablet (<10 kg), 1 tablet (10-19 kg), 1·5 tablets (20-29 kg), 2 tablets (30-39 kg), and 3 tablets (≥40 kg).
Parasite density count, staging, and clearance
In the 2009-2010 study, thick blood films were made from patients prior to the first dose of artesunate (0 h) and then every 6 h until asexual parasitemia was undetectable. 6 In the 2012 study, blood films were made at 0, 2, 4, 6, 8, and 12 h, and then every 6 h until parasitemia was undetectable. Parasite developmental stages at 0 h were estimated as tiny or large rings based on morphological criteria (appendix). After patients completed the study, parasite clearance curves were derived from parasite density counts. The parasite clearance half-life (ie, the time for parasite density to decrease by 50%) was calculated from the slope constant using the parasite clearance estimator (https://www.wwarn.org/research/parasite-clearance-estimator). 15 The half-life was considered interpretable when the R 2 value of the slope regression line was > 0.8.
In-vitro parasite adaptation
In the 2009-2010 study, blood samples were collected into ACD vacutainers (Becton-Dickinson, Franklin Lakes, NJ) at 0 h. Parasitized erythrocytes were cryopreserved in Glycerolyte 57 (Baxter Healthcare Corp., IL) 21 immediately or after short-term cultivation, and stored in liquid nitrogen until use. From 89 patients enrolled, we selected 18 fast-and 20 slow-clearing parasites representing the lower and upper quartiles of the half-life distribution and adapted them to culture as described. 20 Assays were ultimately performed on parasites from 13 fast-and 13 slow-clearing infections; the other 12 selected parasites were excluded from the study because they did not adapt to culture, did not have a corresponding half-life value that was interpretable, or did not show an identical genotype to the parasite originally obtained from the patient (appendix).
Isotopic in-vitro sensitivity testing (ISA)
The In each assay, parasites were exposed to 700 nM DHA or 0·1% DMSO for 6 h, washed with 12 mL RPMI-1640 to remove drug, resuspended in complete medium (RPMI-1640, 0·5% Albumax II, 2% heatinactivated B+ plasma, 50 µg/mL gentamicin), and cultured at 37 o C in a tri-gas atmosphere (5% CO 2 , 5% O 2 , 90% N 2 ). Thin blood smears were prepared and stained with 10% Giemsa (Merck KGaA Darmstadt, Germany) for 20 min. Survival rates were assessed microscopically by counting the proportion of viable parasites that developed into second-generation rings or trophozoites with normal morphology at 66 h (RSA 0-3h ), 57 h (RSA 9-12h ), and 48 h (TSA 18-21h ) after drug removal. For each sample, approximately 10,000 erythrocytes were examined independently by two microscopists who were blinded to each other's data and to half-lives. When the difference between survival rates was >20%, a third blinded microscopist examined the slides. 24 Mean parasite counts were calculated and survival rates expressed as ratios of viable parasitemias in DHA-and DMSO-exposed samples.
Ex-vivo survival assay
In the 2012 study, ex-vivo RSAs were performed on parasites obtained directly from patients (figure 1B).
Two mL of venous blood were collected into ACD vacutainers (Becton-Dickinson) prior to the first Duo-Cotecxin® dose and processed within 24 h. Plasma was removed and the blood washed three times in RPMI-1640. If the parasitemia was >1%, it was adjusted to 1% by adding uninfected erythrocytes. Exvivo RSAs were performed as above except that complete medium did not contain human plasma, parasites were not experimentally synchronized, and three different atmospheres were tested in parallel: tri-gas, 5% CO 2 , and candle jar. Smears made 66 h after drug removal were examined and survival rates calculated as described above. Results were considered interpretable if the parasitemia in the DMSO-exposed sample was higher than the starting parasitemia.
Parasite genotyping
DNA was extracted from 200 μL of whole blood collected in 2010 at 0 h and from corresponding cultureadapted parasites just prior to in-vitro assays using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA).
Parasite genotyping was performed as described. 25 Twelve single nucleotide polymorphisms were assessed using a PCR-LDR-FMA (Polymerase Chain Reaction-Ligase Detection Reaction-Fluorescence
Microspheres Assay) (appendix).
Statistical analysis
Data were analyzed using Microsoft Excel and MedCalc version 12 (Mariakerke, Belgium). Quantitative data were expressed as median (interquartile range, IQR). Stage-dependent patterns of survival were expressed as the difference between RSA 0-3h and TSA 18-21h 
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Results
We culture-adapted parasites from 13 fast-and 13 slow-clearing infections collected in Pursat in 2010 (appendix), and used them in three stage-specific survival assays: RSA 0-3h , RSA 9-12h , and TSA 18-21h ( figure   1A ). For 0-3 h rings (RSA 0-3h ), the median survival rate of slow-clearing parasites was 55-fold higher than that of fast-clearing parasites (10·9% vs. 0·23%; p=0·007) (table; figure 2 ). In contrast, 9-12 h rings and 18-21 h trophozoites from fast-and slow-clearing infections showed no difference in survival (table; figure 2). The stage-dependent survival patterns differed between fast-and slow-clearing parasites (appendix). Specifically, the survival rates of slow-clearing parasites decreased with parasite stage, while those of fast-clearing parasites increased with parasite stage (∆=9·9%, IQR 1·7%-14·4% vs. ∆= -0·3%, IQR -1·1%-0·4%; p=0·007). In an isotope-based sensitivity assay (ISA) that monitored replication of parasites exposed to drug for 48 h, 26 
Discussion
Here we show that P falciparum isolates from slow-and fast-clearing infections in Cambodia respond differently to a 6-h, 700-nM exposure to DHA. In the RSA 0-3h , the 0-3 h rings of slow-clearing parasites had much higher survival rates than those of fast-clearing parasites. In the ex-vivo RSA, survival rates correlated with parasite clearance half-lives. Importantly, the ex-vivo RSA accurately identified slowclearing infections in Cambodian provinces where they have not yet been described. To our knowledge, these are the first reported in-vitro and ex-vivo DHA susceptibility data that correlate with in-vivo parasite clearance half-lives. These data qualify the in-vitro RSA 0-3h as a novel laboratory tool for elucidating the mechanism of artemisinin resistance through biochemical and molecular studies. These may include: genome-wide association studies in which RSA 0-3h survival rates are associated with wholegenome SNP data; 28 phenotypic screening of parasite progeny clones obtained from genetic crosses between artemisinin-sensitive and artemisinin-resistant parental lines; phenotypic characterization of the different artemisinin-resistant parasite subpopulations circulating in western Cambodia; 28 and validation of candidate molecular markers through genetic manipulation of parasites.
The data also indicate that the ex-vivo RSA is a feasible, convenient method for detecting the spread and emergence of artemisinin resistance in areas where it has not yet been reported (eg, eastern Cambodia), or the worsening of artemisinin resistance in areas where it is entrenched (eg, western Cambodia). Both types of findings from ex-vivo RSAs may inform national malaria control programs to expand or intensify containment measures. In a "screen-confirm" approach to support such efforts, we propose that the ex-vivo RSA be used in the field to "screen" for artemisinin-resistant parasites. Any parasite showing DHA resistance in this assay can then be (i) adapted to short-term culture in the laboratory, (ii) genotyped to ensure its identity to the clinical parasite isolate obtained from the patient, and (iii) tested to "confirm" DHA resistance in the in-vitro RSA 0-3h .
For both artemisinin-sensitive and artemisinin-resistant parasites, we demonstrate stage-dependent heterogeneity of DHA susceptibility in ring forms. In artemisinin-sensitive parasites, 0-3 h rings were more susceptible to DHA than 9-12 h rings. This finding with clinical parasite isolates is consistent with the recent observation that 2-4 h rings of artemisinin-sensitive laboratory lines are specifically hypersensitive to DHA. 18 In artemisinin-resistant parasites, on the other hand, 0-3 h rings were less susceptible to DHA than 9-12 h rings. We tentatively conclude that the susceptibility of Cambodian parasites to DHA is controlled predominantly at the 0-3 h stage of parasite development. This interpretation, and our finding that trophozoites are susceptible to DHA regardless of half-life, is consistent with mathematical modeling predictions 29 and transcriptomics data 30 from studies of ringstage parasites.
Half-lives and RSA 0-3h survival rates were 'discordant' in four patients (figure 2, appendix). Three patients (1007, 1006, and 1009) had fast-clearing infections with parasites showing survival rates of 5·3%, 19·3%, and 51·4%, and a resistant stage-dependent pattern (∆=1·2%, 17·3%, and 50·2%, respectively). Their patterns differed from those of fast clearing-infections (∆= -0·7% vs. 17·3%; p=0·01), being similar to those from slow-clearing-infections (∆= 10·3% vs. 17·3%; p=0·56) (appendix). To explain this discordance, we hypothesized that these three parasites had already developed into DHA-susceptible, late ring-stage parasites in the patient's blood at the time of the first artesunate dose.
To investigate this possibility, we reviewed the initial blood smears from these patients and estimated the relative age of their ring-stage parasites just prior to artesunate treatment (appendix). In thin blood smears made at 0 h, we found that these three 'discordant' patients indeed had a 2-fold lower proportion of tiny rings compared to the 12 'concordant' patients from the slow-clearing group (ie, those having slow-clearing infections with DHA-resistant parasites) (42·4% vs.75·0%; p=0·03). Higher proportions of large, older rings could account for shorter than expected half-lives because these forms are more susceptible to DHA than tiny, young rings. Overall, the data suggest that the relative abundance of tiny and large rings at the time of the first artemisinin dose influences the parasite clearance half-life, and that accurate ex-vivo staging of parasites is critical for classifying treatment outcome. In one patient (896) having a slow-clearing infection with a parasite showing a survival rate of 0·2%, and a sensitive stage-dependent pattern (∆= -1·4%) (appendix), we cannot rule out an inadequate immune response to infection 31 or insufficient plasma levels of artemisinins.
The RSA 0-3h survival rate may be critically informative in ongoing parasite genetics studies 28, 32, 33 aimed at identifying loci under artemisinin selection since it is unaffected by in-vivo parameters (eg, pharmacokinetics, hemoglobin type, and acquired immunity) that may influence the parasite clearance half-life. While this phenotype may also be a useful readout in studies to define and validate molecular markers for tracking artemisinin-resistant parasites in the field, the RSA 0-3h is a laborious assay. In contrast, the ex-vivo RSA saves weeks of effort (results are available in 3 days), and avoids the confounding effects of parasite clone elimination and metabolic alterations that may accompany the culture adaptation of parasites. In addition to implementing methodologies that more precisely Here we describe a novel assay, the Ring-stage Survival Assay (RSA), specifically designed to assess the ring-stage susceptibility of P falciparum to DHA. In a retrospective study using culture-adapted parasites, we demonstrate increased survival of 0-3 hour ring-stage parasites from slow-clearing compared to fastclearing infections. In a prospective study, we show that ex-vivo parasite survival rates correlate significantly with in-vivo parasite clearance half-lives, and reliably detect artemisinin-resistant parasites in patients with malaria.
Interpretation
We report for the first time in-vitro and ex-vivo assays that detect artemisinin-resistant, slow-clearing P falciparum parasites in patients with malaria. The in-vitro RSA 0-3h provides a platform for biochemical and molecular characterization of artemisinin resistance. The ex-vivo RSA can be easily implemented in countries where surveillance for artemisinin resistance is needed. 
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Percentage survival in RSA 0-3h , RSA 9-12h , and RSA 18-21h , and IC 50 and IC 90 values for dihydroartemisinin (DHA) and artesunate (ATS) in isotope-based sensitivity assays. P-values for significance from Mann-Whitney test. 
Fast-clearing parasites (Short half-life)
Slow-clearing parasites (Long half-life) p-value
RSA 0-3h Median IQR Range 0·23 0·14-2·93 0·01-51·39 10·88 4·75-13·91 0·16-29·14 0·007 RSA 9-12h Median IQR Range 1·07 0·77-1·70 0·06-10·00 2·12 1·46-3·55 0·33-8·00 0·06 RSA 18-21h Median IQR Range 0·99 0·48-2·20 0·16-4·10 1·16 0·78-2·05 0·38-5·30 0·54 DHA IC 50 Median IQR Range 0·71 0·58-0·94 0·29-1·20 0·79 0·62-0·11 0·42-1·51 0·44 DHA IC 90 Median IQR Range 2·60 2·28-3·30 1·54-4·49 2·46 1·78-3·02 1·48-4·40 0·36 ATS IC 50 Median IQR Range 1·00 0·84-1·47 0·28-1·71 1·11 0·98-1·84 0·83-2·50 0·20 ATS IC 90 Median IQR Range 3·32 2·52-3·94 2·30-5·80 3·02 2·38-3·86 1·99-6·38 0·70
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Parasite clearance half-life (h)
